Extend brand exclusivity: researchers

Share this article:

Researchers led by Duke University professor emeritus of economics Henry Grabowski are urging Congress, in a PhRMA-sponsored study, to extend the exclusivity period for branded drugs by seven years and remove the initial 180-day marketing exclusivity granted to first-to-file generics by the 1984 Waxman-Hatch Amendments.

In a Health Affairs article. they propose that the legislation be re-evaluated in light of  its intended purpose: balancing incentives for generics with innovation.

Their report analyzes data from 1995 to 2008 and finds that the average period of “market exclusivity” has dropped. In addition, Paragraph 4 certification challenges have increased and are occurring sooner after reference-listed drug launch.

A sharply negative response from the Generic Pharmaceutical Association (GPhA) claimed that implementing such “reckless recommendations” would gut the Waxman-Hatch Act, costing consumers and the U.S. health system as much as $1 trillion over the next decade. “Indeed,” the release said, the proposals “would put at risk not only the sustainability of the American healthcare system, but also the national economy.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters